References
1. Belgian Cancer Registry. Obtained via kankerregister.org
2. Cramer SC, Glaspy JA, Efird JT, Louis DN. Chronic lymphocytic
leukemia and the central nervous system: A clinical and pathological
study. Neurology. 1996;46(1):19–25.
3. Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, et al.
Prevalence and characteristics of central nervous system involvement by
chronic lymphocytic leukemia. Haematologica [Internet].
2016;101(4):458–65.
4. Thompson PA, O’Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC,
et al. Complex karyotype is a stronger predictor than del(17p) for an
inferior outcome in relapsed or refractory chronic lymphocytic leukemia
patients treated with ibrutinib-based regimens. Cancer.
2015;121(20):3612–21.
5. Lv L, Sun X, Wu Y, Cui Q, Chen Y, Liu Y. Efficacy and Safety of
Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant
Single-Arm Meta-Analysis. Front Oncol. 2021;11(July):1–14.
6. Illerhaus G, Schorb E, Kasenda B. Novel agents for primary central
nervous system lymphoma: Evidence and perspectives. Blood.
2018;132(7):681–8.
7. Salem AH, Badawi MA, Place AE, Palenski TL, Arrendale R, Kim SY, et
al. Venetoclax Crosses the Blood Brain Barrier: A Pharmacokinetic
Analysis of the Cerebrospinal Fluid in Pediatric Leukemia Patients.
Blood [Internet]. 2020;136(Supplement 1):30–1.
8. Reda G, Cassin R, Dovrtelova G, Matteo C, Giannotta J, D’incalci M,
et al. Venetoclax penetrates in cerebrospinal fluid and may be effective
in chronic lymphocytic leukemia with central nervous system involvement.
Haematologica. 2019;104(5):e222–3.
9. Soumerai JD, Takvorian RW, Sohani AR, Abramson JS, Ferry JA.
Venetoclax activity in a patient with central nervous system involvement
by chronic lymphocytic leukaemia. Lancet Haematol [Internet].
2022;9(10):e796.
10. Karbhari N, Lara-Martinez H, Hill, JM. Venetoclax: A Novel
Therapeutic Agent for CLL with CNS Involvement. Case Rep Oncol.
2022;15(1):345–50.
11. ClinicalTrials.gov [Internet]. Bethesda (MD) NL of M (US).
Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma
(VENOBI-CNS). Identifier: NCT04073147 [Internet]. 2019;
12. ClinicalTrials.gov [Internet]. Bethesda (MD) NL of M (US).
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With
Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the
Central Nervous System [Internet]. Identifier: NCT05211336. 2022.